Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

Three things in AI to watch, according to a Nobel-winning economist

View original at technologyreview.com
MIT Technology Review - Ai Research Title: Three things in AI to watch, according to a Nobel-winning economist Date: 2026-05-11 17:35 Source: https://www.technologyreview.com/2026/05/11/1137090/three-things-in-ai-to-watch-according-to-a-nobel-winning-economist/ <p><em>This story originally appeared in The Algorithm, ou…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Some of the most influential research about AI's impact on work may increasingly come from the companies with the most to gain from favorable conclusions, which is a concerning dynamic

    60% confidence
  • There is a huge amount of uncertainty in the AI economy; conflicting signals will persist — anecdotes about worsening job markets for college graduates alongside no measurable effect on productivity

    60% confidence
  • AI agents are better thought of as tools to augment particular pieces of someone's work than something malleable enough to handle a person's whole job

    60% confidence
  • Corporate AI use should be taxed and workers displaced by AI-driven layoffs should receive compensation as part of a jobs guarantee

    60% confidence
  • Using AI agents as a one-to-many replacement for human workers is a losing proposition

    60% confidence
  • AI companies have strong incentives to shape the economic narrative around their technology, raising the risk that in-house economists are hired to further viewpoints or hype rather than conduct genuine research

    60% confidence
  • AI would give only a small boost to US productivity and would not obviate the need for human work; it is okay at automating certain tasks, but some jobs will be perfectly fine

    60% confidence
  • One of the key signals to watch for AI's economic impact is the creation of apps that make AI easier for average workers to use productively

    60% confidence
  • It makes sense for AI companies to hire economists because public skepticism about AI — largely driven by job concerns — is growing

    60% confidence
  • Some previously skeptical economists have become more open to the idea that AI could cause seismic disruption to the labor market

    60% confidence
  • Studies repeatedly find that AI is not affecting employment rates or layoffs

    60% confidence
  • Whether AI agents will supercharge AI's impact on jobs depends on whether they can eventually handle the orchestration between tasks that humans do naturally; many jobs will be spared if agents cannot fluidly switch between tasks

    60% confidence
  • AI has not yet seen the development of apps with the same usability as transformative software like PowerPoint or Microsoft Word, which is why AI has not yet shown a seismic impact on the job market or economy

    60% confidence
  • An x-ray technician juggles 30 different tasks — from taking patient histories to organizing mammogram archives — and an AI would need many individual tools or protocols to replicate the natural switching a human does

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,351 source documents archived
Query this data → isubstrate.com